Scarica l'app Stockscreener
2.515
0.04%
0.005
Organogenesis Holdings Inc Borsa (ORGO) Ultime notizie
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
3 Penny Stocks With Market Caps Under $400M To Consider - simplywall.st
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens - FinancialContent
Organogenesis shares jump 20% following positive clinical trial results - MSN
What's going on with Organogenesis stock on Wednesday? - MSN
Options Flow: Will Organogenesis Holdings Inc benefit from rate cuts2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
720p-h264Dailyhunt - Dailyhunt
What's Going On With Organogenesis Stock On Wednesday? - Sahm
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight (NASDAQ:ORGO) - Seeking Alpha
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
Organogenesis stock rockets after diabetic foot ulcer trial posts statistically significant win - MSN
PuraPly AM Triumphs in Wound Healing Trial, Paves Way for New Successes - StocksToTrade
Organogenesis’ Clinical Trials Propel Stock Amid FDA Progress - timothysykes.com
Organogenesis stock surges 20% on trial results By Investing.com - Investing.com Australia
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win - Benzinga
Organogenesis stock surges 20% on trial results - Investing.com
Organogenesis stock up as PuraPlyAM succeeds (ORGO:NASDAQ) - Seeking Alpha
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 - Bitget
Organogenesis plans rolling BLA submission for ReNu by year-end - Investing.com Canada
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPlyAM - Bitget
ORGO Stock Rallies After Hours On Clearing Regulatory Pathway For Pain Relief Treatment - Stocktwits
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM - The Manila Times
In 170-patient diabetic foot ulcer study, Organogenesis clears key goal - Stock Titan
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain - Bitget
Organogenesis Cleared to Begin Rolling BLA for ReNu Knee Osteoarthritis Therapy - marketscreener.com
Regenerative medicine giant Organogenesis Holdings Inc (ORGO) recently announced the successful completion of a key meeting with the U.S. Food and Drug Administration (FDA). - Bitget
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain - The Manila Times
Knee pain treatment for 31 million Americans moves toward FDA filing - stocktitan.net
New York real estate firm acquires Organogenesis property for $68M - Providence Business News
ORGO SEC FilingsOrganogenesis Hldgs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Movement Recap: Whats the fair value of Organogenesis Holdings Inc stockQuarterly Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Published on: 2026-03-31 10:52:09 - baoquankhu1.vn
IPO Launch: Is Organogenesis Holdings Inc impacted by rising rates2026 Historical Comparison & High Conviction Buy Zone Alerts - baoquankhu1.vn
Dividend Watch: Whats the fair value of Organogenesis Holdings Inc stock2026 Technicals & Weekly High Conviction Ideas - baoquankhu1.vn
Organogenesis Facing Hard Times As It Adjusts To CMS Rule Changes (NASDAQ:ORGO) - Seeking Alpha
Asia Pacific Wound Care Biologics Market Projected to Witness - openPR.com
Organogenesis (NASDAQ:ORGO) Receives “Buy” Rating from BTIG Research - Defense World
BTIG Reiterates Buy Rating and $8 Price Target for ORGO | ORGO S - GuruFocus
Assenagon Asset Management S.A. Acquires 680,392 Shares of Organogenesis $ORGO - MarketBeat
Income Plays: Is Organogenesis Holdings Inc benefiting from innovation trendsDividend Hike & Target Return Focused Picks - baoquankhu1.vn
1.68%
0.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):